In this episode of The Value Brief, host Tiffany Huth, Director of Policy and Research at the Center for Innovation & Value Research, is joined by Maia Lange, Chief Policy Officer at iXCells and Silas Martin, Head of Access and Policy Research at Johnson & Johnson, for a deep discussion on drug pricing reform and what it means to move beyond cost alone.

This episode is Part 1 of a two-part conversation.

Building on conversations from the 2025 Fall Policy Summit in Washington, D.C., the episode explores why patient-centered value must include affordability, access, innovation, and lived experience. The discussion examines the limitations of cost-focused frameworks, the risks of relying too heavily on international pricing models, and why U.S.-specific approaches are essential to meeting diverse patient needs.

Maia and Silas share perspectives from both advocacy and industry, highlighting the importance of early and continuous patient engagement, recognizing heterogeneity across populations, and designing policies that support timely access without slowing innovation.